Horizon Pharma to pay $800M for rare disease drug developer

SHARE Horizon Pharma to pay $800M for rare disease drug developer
horizonpharmalogo_2.jpg

Horizon Pharma will spend about $800 million to buy Raptor Pharmaceutical and expand its portfolio of rare disease treatments, a growing area of focus for drugmakers.

Horizon Pharma, whose U.S. headquarters is in Deerfield, said Monday that the deal will strengthen its business in the United States and provide a platform to expand in Europe and other international markets.

Raptor’s portfolio includes Procysbi, which treats a rare metabolic disorder, and Quinsair, approved for managing a chronic pulmonary infection in adult patients with cystic fibrosis.

Ireland-based drug developer Horizon Pharma Plc. will pay $9 in cash for each share of Novato, California-based Raptor Pharmaceutical Corp. and expects to close the deal in the fourth quarter.

Drugmakers in recent years have been shifting more money to developing rare disease treatments, as mass-market drugs lose patent protections.

New York-traded shares of Horizon Pharma rose $1.33, or 7.7 percent, to $18.59 in afternoon trading. Shares of Raptor Pharmaceutical jumped $1.51, or 20.2 percent, to $8.96.

The Latest
Despite getting into foul trouble, which limited him to just six minutes in the second half, Shannon finished with 29 points, five rebounds and two assists.
Cowboy hats, bell-bottoms and boots were on full display Thursday night as fans lined up for the first of his three sold-out shows.
The incident occurred about 3:40 p.m. near Minooka. The horse was successfully placed back into the trailer, and the highway reopened about 40 minutes later. No injuries were reported.
The Hawks conceded the game’s only two goals within the first seven minutes and were shut out for the 12th time this season in a 2-0 defeat Thursday.